Nxera Pharma and PrecisionLife expand R&D partnership into new area

Japan’s Nxera Pharma (TYO 4565) has expanded its strategic R&D partnership with UK-based computational biology company PrecisionLife into autoimmune disorders with the potential to identify new drug targets for the treatment of complex, chronic conditions.

This is the latest in a series of collaborative agreements between Nxera (formerly Sosei Heptares) and PrecisionLife, which began in 2022. The partnership aims to establish new drug targets and subsequently potential precision targeted therapies for autoimmune disorders, each linked to subgroups of patients by PrecisionLife’s mechanism-based patient stratification biomarkers.

PrecisionLife finds combinations of biological features that together are associated with disease risk and/or protective effects. These combinations, along with mechanistic biomarkers and causal biology insights to identify which patients will respond to treatment, may empower Nxera to more accurately position known and novel targets for the right responder populations in each target product profile.